Sio Gene Therapies Inc

Sio Gene Therapies — Axovant Sciences — Corporate Update (June 2018)

19 slides from Sio Gene Therapies's corporate update, Jun 6, 2018

  1. Slide 1: Forward Looking Statements

    FORWARD LOOKING STATEMENTS Statements made in this presentation contain forward-looking statements, including statements regarding Axovant’s expectations about timing of the results for the Phase 1/2 clinical study for AXO-Lenti-PD in Parkinson’s disease, expected outcomes of planned clinical develo

  2. Slide 2: Building a leader in innovative CNS therapies

    Building a leader in innovative CNS therapies AXO-Lenti-PD: potential best-in-class gene therapy for Parkinson’s disease Delivery of three genes that encode critical enzymes necessary for endogenous dopamine synthesis in the brain (AADC, TH, and CH1) using lentiviral vector Plan to initiate Phase 1/

  3. Slide 3: New additions to leadership team bring decades of gene therapy and CNS expertise

    Michael Hayden, MB ChB, Ph.D. Senior Scientific Advisor and Chairman, Axovant Scientific Advisory Board Former President, Global R&D, and Chief Scientific Officer, Teva GLYBERA®, first-ever approved gene therapy, was initially conceived in Hayden’s lab Killam Professor of Medical Genetics, Universit

  4. Slide 4: Track record of rapid clinical execution in neurology

    Track record of rapid clinical execution in neurology Global leader in gene therapy with 20+ years of experience Demonstrated manufacturing capabilities for commercially available gene therapy products Extensive drug development experience in neurodegeneration

  5. Slide 5: Parkinson's disease is a progressive neurodegenerative disorder

    Parkinson’s disease (PD) is a progressive neurodegenerative disorder resulting in the loss of dopamine in the striatum Motor symptoms can include tremor, rigidity, and bradykinesia PD affects approximately 1% of adults over the age of 60, or 7-10 million patients worldwide Current standard of care i

  6. Slide 6: AXO-Lenti-PD: a novel gene therapy for Parkinson's disease

    AXO-Lenti-PD: a novel gene therapy for Parkinson’s disease AXO-Lenti-PD contains three genes that encode the critical enzymes required for endogenous dopamine synthesis Tyrosine hydroxylase (TH): converts tyrosine to L-dopa Cyclohydrolase 1 (CH1): rate-limiting enzyme for synthesis of essential cofa

  7. Slide 7: AXO-Lenti-PD: designed to reduce motor fluctuations in Parkinson's disease

    AXO-Lenti-PD: designed to reduce motor fluctuations in Parkinson’s disease AXO-Lenti-PD’s novel 3-gene therapy approach is designed to (1) increase basal dopamine production and (2) reduce dopamine variability GOALS OF THERAPY: Less troublesome dyskinesia Less OFF time More ON time Lower requirement

  8. Slide 8: Why use lentiviral vector?

    Why use lentiviral vector? Large vector packaging capacity enables efficient delivery of multiple genes in a single cassette Lentiviral vectors are capable of integrating into the host genome, which may help maintain long-term stable transgene expression To date, well-tolerated with limited treatmen

  9. Slide 9: ProSavin: proof of concept from earlier vector construct

    ProSavin was the predecessor therapy to AXO-Lenti-PD Delivery of three genes in the same lentiviral vector as AXO-Lenti-PD, but in a different payload configuration One-time MRI-guided stereotactic delivery Phase 1/2 study of ProSavin in patients with advanced Parkinson’s disease (n=15) completed Me

  10. Slide 10: ProSavin: completed Phase 1/2 study design

    Phase 1/2 study completed in patients with advanced Parkinson’s disease (n=15) Study was conducted in UK and France Results published in The Lancet (Palfi, 2014) Cohorts in dose-escalation paradigm: Cohort 1: Low dose (1.9 x 107 TU) Cohort 2a: Mid dose (4.0 x 107 TU) Cohort 2b: Mid dose (4.0 x 107 T

  11. Slide 11: ProSavin: multiple doses evaluated in Phase 1/2 study

    ProSavin: multiple doses evaluated in Phase 1/2 study Source: Palfi S, Gurruchaga JM, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. The Lancet. January 2014. http://dx.doi.org/10.1

  12. Slide 12: ProSavin: sustained response observed several years after administration

    ProSavin: sustained response observed several years after administration Durable effects seen through 4 years after one-time administration of ProSavin UPDRS Part III (motor) “OFF” scores are typically expected to worsen by 3-4 points/year in this population* Mean UPDRS III (OFF) scores pooled acros

  13. Slide 13: AXO-Lenti-PD: a re-engineered gene therapy product

    AXO-Lenti-PD: a re-engineered gene therapy product AXO-Lenti-PD was the product of multifactorial experimentation to modify the payload configuration to improve dopamine production Different ordering of genes Balanced stoichiometry of transgene expression to ensure consistent 1:1 production of TH an

  14. Slide 14: AXO-Lenti-PD: increases catecholamine production compared to ProSavin

    AXO-Lenti-PD: increases catecholamine production compared to ProSavin AXO-Lenti-PD achieved up to 10-fold increase in dopamine + L-Dopa production compared to ProSavin Production of catecholamines (L-dopa & Dopamine) in Primary Human Neurons with ProSavin and AXO-Lenti-PD AXO-Lenti-PD ProSavin

  15. Slide 15: AXO-Lenti-PD: anticipated Phase 1/2 study design

    AXO-Lenti-PD: anticipated phase 1/2 study design First patient expected to be dosed by end of 2018 Study will capture sham-controlled data during Part B Delivery method: one-time MRI-guided stereotactic delivery with automatic pump Key assessments: Safety and tolerability, Biomarkers, UPDRS scores a

  16. Slide 16: Oxford BioMedica: our clinical and commercial manufacturing partner

    Oxford BioMedica: our clinical and commercial manufacturing partner An industry leader in GMP lentiviral vector manufacturing and commercial production Commercial-grade vector manufacturing GMP cell banks for adherent and suspension processes Certified clean room capacity across three independent su

  17. Slide 17: Financial terms of transaction

    Financial terms of transaction Upfront $30M in cash Including $5M pre-payment for manufacturing services Development Milestones (total) $55.0M Regulatory and Commercial Milestones (total) $757.5M Royalties on Net Sales 7% on annual net sales < $1B 8% on annual net sales > $1B and < $2.5B 9% on annua

  18. Slide 18: Plans for continued pipeline expansion

    Plans for continued pipeline expansion CNS-targeted gene therapies Parkinson’s disease and related neurodegenerative conditions AXO-Lenti-PD More pipeline expansion expected along these verticals in FY2018

  19. Slide 19: Plans for continued pipeline expansion

    Plans for continued pipeline expansion AXO-Lenti-PD Parkinson's disease and related neurodegenerative conditions More pipeline expansion expected along these verticals in FY2018 AXOVANT

Axovant Sciences — Corporate Update (June 2018) on 6ix